Company Revenue

The company continued its strong performance in the second quarter amid integration efforts and raised 2024 pro forma guidance....

The company grew 25% in the second quarter of 2024, taking people and market share from spine's incumbent players....

The company's MACI sales grew over 20% in the second quarter of 2024 as biopsy rates and conversions ramp up...

The company's orthopedic sale grew in the mid single digits during the second quarter as its transformation plan shows results....

The company's sales declined in the low single digits in the second quarter of 2024 amid a bevy of ongoing...

The company's orthopedic sales grew in the high single digits during the second quarter on healthy procedure volume and commercial...

The company celebrated its 25th anniversary with a world tour of scientific events and continued above-market growth in 2024's first...

The company continued its strong performance in 2024 with sales and regulatory wins, and now expects 2024 growth of more...

The company grew in the low single digits for the second quarter of 2024 but saw strong knee and hip...

The company leveraged it's differentiated and broad enabling technology ecosystem to drive implant and biologics sales growth....